Kathryn Yang

Kathryn Yang

Auto-generated profile, based on publicly available information

Kathryn Yang

Movement Disorders Program, Department of Neurology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Neurology
Verified
Journal Article
Closed access
ABArjun Balachandar
Arjun Balachandar
LVLeonard H. Verhey
Leonard H. Verhey
KMKarim Mithani
Karim Mithani
HSHrishikesh Suresh
Hrishikesh Suresh
EKElizabeth N. Kerr
Elizabeth N. Kerr
GIGeorge M. Ibrahim
George M. Ibrahim
Deep brain stimulation (DBS) is considered off-label and investigational in pediatric populations with some exceptions. There are limited data on the relative rates of complications after DBS across different indications and targets in children. This study aimed to evaluate the safety of DBS surgery for children with movement disorders (MDs; dystonia, chorea, or tic disorders), drug-resistant epilepsy (DRE), or neurodevelopmental disorders, namely, self-injurious behavior (SIB). Data were collected both prospectively and retrospectively from children implanted with DBS through the North American multicenter Child and Youth CompreHensIve Longitudinal Database for Deep Brain Stimulation and included demographic, clinical, operative, and postoperative variables. Complications included infection, noninfectious surgical site findings (dehiscence or seroma), hardware-related issues (disconnection or impedance change), intracranial injury, or other complications. The primary outcome was major complications, defined as any adverse event causing permanent neurologic injury or requiring surgical intervention. The secondary outcome was minor complications, defined as nonmajor complications. Generalized linear models were used to assess for any significant associations with complications. A total of 130 children and youth (mean age 12.2 ± 4.2; range 3-18) years and weighing 12.5-126.6 kg underwent DBS. The most common indication was MD (77, 59.2%), followed by DRE (47, 36.2%) and SIB (6, 4.6%). Major complications occurred in 11.5%, with a greater likelihood in MD (n = 12, 15.6%) compared with DRE (n = 2, 4.3%; odds ratio [OR] 3.55, 95% CI 2.66-4.73, p < 0.001) and significantly associated with lower weight at surgery (p < 0.001) and urgent intervention (p = 0.028). These included infection (6.2%), hardware malfunction (3.1%), and wound dehiscence (0.8%). Minor complications were also higher with MD compared with DRE (OR 1.83, 95% CI 1.16-2.89, p = 0.010) occurring in 22 participants (16.9%; 14 MD, 7 DRE, 1 SIB), including infection (6.2%), high impedance (1.5%), unrelated hydrocephalus (0.8%), perioperative worsening of symptoms (3.8%), incidental tract hemorrhage (2.3%), and noninfectious peri-electrode cystic changes (0.8%). DBS-associated complications were low across multiple pediatric indications and targets, with MD associated with higher risk of major complications. Limitations include a focus on surgical postoperative complications and not stimulation-related adverse outcomes. These findings demonstrate the safety profile of DBS in children in a large cohort.

24 January 2026 in Movement Disorders
Verified
Journal Article
Closed access
MTMoritz Thiel
Moritz Thiel
KBKaterina Bernardi
Katerina Bernardi
ESEnrique Gonzalez Saez‐Diez
Enrique Gonzalez Saez‐Diez
JRJoshua Rong
Joshua Rong
NDNathalie Dorison
Nathalie Dorison
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari

6 September 2024 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
KYKathryn Yang
Kathryn Yang
VQVicente Quiroz
Vicente Quiroz
ATAmy Tam
Amy Tam
RSRasha Srouji
Rasha Srouji
XVXimena Villanueva
Ximena Villanueva
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari
Juvenile‐onset Huntington's disease (HD) is a rare subset of HD with symptom‐onset before the age of 18. In contrast to the adult population, children present early‐on with behavioral, psychiatric, and cognitive symptoms, in addition to a diverse spectrum of movement disorders. This poses a distinct challenge in diagnosis and management. We here describe the spectrum of movement disorders, accompanied with detailed video recordings, in seven cases of juvenile‐onset HD. Our findings highlight early cognitive and behavioral symptoms, preceding motor symptoms. The diverse movement disorder phenotypes included dystonia, Parkinsonism, myoclonus, and chorea, findings which underscore the heterogeneity of presenting symptoms.

8 January 2026 in Movement Disorders
Verified
Journal Article
Closed access
JRJoshua Rong
Joshua Rong
KBKaterina Bernardi
Katerina Bernardi
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari
KYKathryn Yang
Kathryn Yang

18 March 2026 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
KBKaterina Bernardi
Katerina Bernardi
AZAnna Zhou
Anna Zhou
KYKathryn Yang
Kathryn Yang
JRJoshua Rong
Joshua Rong
VQVicente Quiroz
Vicente Quiroz
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari

5 May 2026 in Brain
Verified
Journal Article
Closed access
JAJulian E Alecu
Julian E Alecu
LSLuca M Schierbaum
Luca M Schierbaum
ATAmy Tam
Amy Tam
VQVicente Quiroz
Vicente Quiroz
KBKaterina Bernardi
Katerina Bernardi
DEDarius Ebrahimi-Fakhari
Darius Ebrahimi-Fakhari
Hereditary spastic paraplegia type 4 (SPG4), caused by variants in SPAST, is the most common form of hereditary spastic paraplegia and exhibits a remarkable phenotypic heterogeneity ranging from late-onset pure presentations to severe, early-onset complex disease. Robust genotype–phenotype correlations and detailed natural history data are lacking, limiting clinical trial readiness. We analysed 206 patients with genetically confirmed SPG4 enrolled across seven international centres, complemented by high-quality literature-derived cases. Deep phenotyping included standardized motor scales, spasticity ratings, developmental milestones and patient-reported outcomes. We developed an extended essentiality-mapping framework to classify SPAST missense variants by integrating in silico pathogenicity predictions, evolutionary constraint, physicochemical residue connectivity and variant enrichment within the human spastin hexamer structure. Plasma neurofilament light chain (pNfL) using was quantified using single-molecule array (Simoa) in 26 patients and 101 controls. We identified 136 distinct SPAST variants, including 10 novel variants. Variant class segregated strongly by inheritance, with de novo cases enriched for missense variants and inherited cases showing a variety of variant classes with enrichment for truncating variants. Longitudinal analysis revealed two latent trajectories: a rapidly progressive severe subgroup enriched for de novo missense variants and a biphasic moderate subgroup enriched for inherited truncating variants. Patient stratification integrating spastin essentiality mapping (missense variants affecting essential, neutral or context-dependent residues) with established genetic modifiers (biallelic pathogenic variants or modifier variants in trans) classified patients into predicted severe and moderate subgroups with divergent age at onset and clinical disease progression. The severe subgroup showed early developmental delays, rapid loss of ambulation and declining quality of life, whereas the moderate subgroup displayed delayed but accelerating disease progression. Levels of pNfL were elevated in both subgroups, most pronounced in severe early disease. This study provides the most detailed natural history of SPG4 to date and introduces a biologically informed stratification framework that links variant class and location to divergent clinical trajectories. These data establish clinically meaningful benchmarks and offer a genotype-based framework to improve anticipatory care and optimize trial design for SPG4.